What is a Biological Computer?

At its core, a biological computer, or what Cortical Labs calls “Synthetic Biological Intelligence,” is a hybrid of living tissue and silicon hardware. The CL1 system cultivates human brain cells on a microelectrode array. This array acts as a bridge, allowing for two-way communication between the neurons and a computer. The neurons can receive input, learn, and even act on their environment, all while being sustained by a sophisticated life-support system.

This isn’t just a theoretical concept. In 2022, Cortical Labs famously taught a cluster of these neurons to play the classic video game Pong. The neurons learned to control the paddle, demonstrating an ability to perform goal-directed tasks. This experiment was a pivotal proof-of-concept, showcasing the incredible potential of harnessing the innate intelligence of brain cells.

The Power of “Wetware-as-a-Service”

One of the most innovative aspects of the CL1 is its accessibility. Through their cloud platform, Cortical Labs offers “Wetware-as-a-Service.” This allows researchers and developers from around the globe to remotely access and experiment with these biological neural networks without needing a specialized lab. This democratization of technology is poised to accelerate discovery and innovation in a multitude of fields.

Revolutionizing Medicine and Drug Discovery

The most immediate and profound impact of the CL1 is likely to be in the medical field. By using human neurons, researchers can create highly accurate models of the human brain. This has the potential to revolutionize how we study and treat neurological diseases like Alzheimer’s, Parkinson’s, and epilepsy.

Instead of relying on animal models, which often don’t translate perfectly to human biology, scientists can test the effects of new drugs directly on human neural tissue. This could dramatically speed up the drug discovery process, reduce costs, and lead to more effective and personalized treatments. Imagine being able to test a new Alzheimer’s drug on a model of a patient’s own neurons, providing a level of precision medicine that was previously unimaginable.

The Next Generation of Artificial Intelligence

While traditional AI has made incredible strides, it has its limitations. Training large language models, for example, requires vast amounts of data and consumes enormous amounts of energy. Biological computers like the CL1 offer a more efficient and sustainable path forward.

Because they are powered by living neurons, these systems can learn from small datasets much faster and with a fraction of the energy consumption of their silicon-based counterparts. The CL1’s neurons can self-organize and adapt, exhibiting a form of “fluid intelligence” that current AI struggles to replicate. This could lead to the development of truly autonomous and adaptive AI systems that can solve complex problems in ways we can’t yet fathom.

A New Era of Computing

The CL1 represents a paradigm shift in computing. It’s a move away from the rigid, binary world of traditional computers and towards a more organic, adaptive, and efficient form of intelligence. The potential applications are vast and varied, from creating more sophisticated brain-machine interfaces to developing ultra-efficient, low-power computing solutions.

We are still in the early days of this technology, and scientists are just beginning to unlock its full potential. However, the launch of the CL1 marks a significant milestone. It’s the dawn of a new era where biology and technology are merging in ways we’ve only dreamed of. The future of computing may not be just about faster chips and more powerful processors; it may be about harnessing the incredible power of life itself.

The post Biological Computing – How Human Brain Cells Are Powering the Next Tech Revolution first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

It appears that our mitochondrial DNA—the crucial genetic code of our cellular powerhouses—doesn’t accumulate mutations in eggs as women age. This stunning discovery suggests that human oocytes may have evolved an elegant and highly effective mechanism to shield their mitochondrial blueprint from the ravages of time, rewriting a major chapter in our understanding of fertility, aging, and evolution.

Understanding the Mitochondrial Legacy: The Mother’s Gift

To grasp the significance of this finding, we first need to understand mitochondria. Often called the “powerhouses” of our cells, these tiny organelles are responsible for generating most of the cell’s supply of adenosine triphosphate (ATP), the molecule that provides the energy for everything from muscle contraction to nerve impulses.

Each mitochondrion contains its own small loop of DNA, known as mitochondrial DNA or mtDNA. Unlike the nuclear DNA in our chromosomes, which is a mix from both parents, mtDNA is inherited exclusively from our mothers. The egg cell, or oocyte, contains a massive stockpile of mitochondria that will power the development of the embryo after fertilization. As Dr. Ruth Lehmann at MIT notes, “The oocyte provides this stockpile.”

While most mutations in mtDNA are harmless, some can lead to serious and debilitating mitochondrial diseases. These conditions often affect tissues with high energy demands, like the brain, nerves, and muscles. Therefore, ensuring the quality of the mtDNA passed from mother to child is critical for the health of the next generation.

Challenging a Long-Held Assumption in Fertility Science

The link between advanced maternal age and an increased risk of chromosomal issues, such as Down syndrome, is undisputed. This occurs because eggs can remain in a state of suspended animation for decades, and over time, the cellular machinery responsible for correctly sorting chromosomes can falter.

Given this reality, scientists logically extrapolated that a similar age-related decline would affect mitochondrial DNA. It was assumed that mtDNA, like any other part of the cell, would be susceptible to damage and mutation over the years. The prevailing wisdom suggested that older mothers would inevitably pass on a higher number of mtDNA mutations to their children. As it turns out, this assumption may be entirely wrong.

The Landmark Study: A Closer Look at the Evidence

To investigate this long-held belief, a research team led by Kateryna Makova at Penn State University employed a highly sensitive DNA-sequencing method. They analyzed the mitochondrial DNA from 80 egg cells collected from 22 women, ranging in age from 20 to 42. Their goal was to identify any de novo mutations—new genetic changes that appeared in the eggs but were not present in the mother’s own cells.

The results were astonishing. The team found no statistical correlation between a woman’s age and the number of mtDNA mutations in her eggs. A 42-year-old woman’s eggs were just as likely to have a low number of mutations as a 20-year-old’s.

To confirm this wasn’t a body-wide phenomenon, they also sequenced the mtDNA from the women’s blood and salivary cells. In stark contrast to the eggs, these cells did show a clear increase in mutations with age. This crucial comparison demonstrated that the oocyte is unique—a specially protected environment where the normal rules of genetic aging don’t seem to apply.

An Evolutionary Masterpiece? The ‘Germline Shield’ Hypothesis

This discovery begs a profound question: Why are egg cells so special? The researchers propose that humans have evolved a sophisticated biological mechanism to protect the integrity of the germline—the cells that create the next generation. As Dr. Makova speculates, “I think that we evolved a mechanism to somehow lower our mutation burden, because we can reproduce later in life.”

This “germline shield” could work in several ways. One theory is that the oocyte may have a highly efficient DNA repair system specifically for mitochondria. Another possibility is a process of cellular “quality control,” where eggs with a high load of mitochondrial mutations are systematically eliminated before they have a chance to mature and be ovulated. This ensures that only the healthiest eggs, with the most pristine mitochondrial stockpile, are available for fertilization. This evolutionary advantage would be immense, allowing for healthier offspring even as humans began reproducing at later ages.

Conclusion: A New Frontier in Reproductive Health

This landmark study represents a significant paradigm shift in reproductive biology. While it doesn’t erase the known risks associated with chromosomal abnormalities and maternal age, it provides a fascinating and hopeful counter-narrative. It reveals that nature has gone to extraordinary lengths to protect the most fundamental energy source we pass on to our children.

The next step for scientists is to pinpoint the exact biological mechanism responsible for this mitochondrial protection. Unlocking that secret could not only deepen our understanding of human evolution but could one day open new doors for therapies related to mitochondrial disease and even some aspects of fertility. For now, the discovery stands as a beautiful testament to the elegance and resilience of human biology, reminding us that there are still profound secrets waiting to be uncovered within our own cells.

The post Mother’s Super Power: How Human Eggs Outsmart Genetic Aging first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

More Than Just Hair – The Psychological Weight of Alopecia

For millennia, the slow, creeping retreat of a hairline has been a source of quiet resignation and, for many, profound distress. Hair loss, or alopecia, is a near-universal human experience, affecting up to 80% of men and 40% of women over their lifetimes. It is far more than a simple cosmetic inconvenience; it is a medical condition with a significant psychological toll, often impacting self-esteem and mental well-being. The global market for hair loss prevention products, a testament to this deep-seated concern, was valued at over $23 billion in 2021 and is projected to climb past $31 billion by 2028.   

This vast market is saturated with treatments ranging from questionable “miracle” lotions to legitimate, albeit limited, medications. For decades, the frontline of this battle has been held by two FDA-approved drugs: minoxidil (Rogaine) and finasteride (Propecia). While they have offered a glimmer of hope, their effectiveness is often partial, inconsistent, and comes with potential side effects. Many users find themselves fighting a defensive war, slowing the loss or coaxing the growth of fine, wispy “vellus” hairs rather than achieving true restoration.   

This long history of partial victories and persistent frustration is precisely why a recent breakthrough from a team of scientists at the University of California, Los Angeles (UCLA) has generated such intense excitement. They have not just developed another weapon for the existing arsenal; they have unveiled a fundamentally new strategy. Their work suggests a future where we no longer just manage hair loss but may be able to reverse it by awakening the body’s own dormant regenerative power. This is the story of a molecule that could restart an engine that was never truly broken, just switched off.   

The UCLA Triumvirate: A Convergence of Minds

The origin of this potential revolution lies not in a dedicated hair loss clinic, but at the intersection of three distinct and powerful scientific disciplines, embodied by a trio of UCLA researchers: William Lowry, Heather Christofk, and Michael Jung. Their collaboration represents a perfect storm of expertise, and remarkably, their groundbreaking discovery in hair restoration was an elegant byproduct of their primary research into the fundamental mechanisms of cancer and stem cell biology.   

William Lowry, Ph.D., is a professor of molecular, cell, and developmental biology and a leading expert in stem cells.His laboratory has long focused on how adult stem cells, particularly the hair follicle stem cells (HFSCs), are regulated. These cells are responsible for the cyclical regeneration of hair, and understanding their behavior is critical. Dr. Lowry’s research delved into how these stem cells maintain tissue and how that process can go awry, leading to cancers like squamous cell carcinoma. It was during this deep dive into the basic biology of the hair follicle that his lab uncovered a unique metabolic profile that governs whether these stem cells are active or dormant.   

Heather Christofk, Ph.D., is a professor of biological chemistry and a maestro of cellular metabolism. Her work explores how cells—from virally infected cells to cancer cells—reprogram their metabolism to fuel their specific needs, whether it be rapid division or survival. Dr. Christofk’s research established a bi-directional relationship: a cell’s state changes its metabolism, but conversely, changing a cell’s metabolism can drive a change in its state. This concept proved to be the lynchpin. By collaborating with Dr. Lowry, she helped decipher the specific metabolic processes that keep hair follicle stem cells “asleep” and, crucially, how to manipulate those processes to wake them up.   

Michael Jung, Ph.D., is a distinguished professor of chemistry and a master molecule builder. A world-renowned medicinal chemist, Dr. Jung specializes in designing and synthesizing novel molecules to serve as drugs for a vast range of human diseases. His credibility is immense; he is a co-inventor of two blockbuster, FDA-approved prostate cancer drugs, enzalutamide (Xtandi) and apalutamide (Erleada). When Lowry and Christofk identified the biological target for reawakening hair follicles, it was Jung’s expertise that allowed them to design and create the precise molecular key to fit that lock: a small molecule that could effectively and safely execute the desired biological command.   

This convergence of expertise—in stem cell biology, cellular metabolism, and medicinal chemistry—allowed the team to identify a biological target, understand its function, and design a drug to manipulate it. The result is a molecule they dubbed PP405.   

Part II: The Science of Resurrection: How to Wake a Sleeping Follicle

The “Metabolic Switch”: It’s Not Magic, It’s Metabolism

The core innovation behind PP405 is a radical departure from previous hair loss treatments. It doesn’t focus on external factors like hormones or blood flow. Instead, it works from the inside out, targeting the fundamental energy-producing machinery within the hair follicle stem cells themselves.   

The central discovery is that in common forms of hair loss, such as androgenetic alopecia, the hair follicle stem cells are not dead or absent; they are simply “stuck” in a dormant or quiescent state, known as the telogen phase of the hair cycle.Imagine an engine that is perfectly functional but has been switched off. Previous treatments have tried to push the car or improve the fuel line, with limited success. The UCLA team found the ignition switch.   

This switch is a metabolic one. Regenerating cells, like those active in a growing hair follicle, have a distinct metabolic signature. They favor a rapid, oxygen-independent energy production process called glycolysis. Dormant cells, by contrast, tend to rely on a more efficient, oxygen-dependent process within the mitochondria. The key to waking the dormant stem cells, the researchers found, was to force them to switch their metabolic preference back to the regenerative, glycolytic state.   

This is precisely what PP405 does. It is a potent inhibitor of a protein called the mitochondrial pyruvate carrier (MPC).The MPC acts as a gatekeeper, controlling the entry of pyruvate—a key fuel molecule derived from glucose—into the mitochondria. By blocking this gate, PP405 effectively starves the mitochondria of their primary fuel source. This forces the cell to ramp up glycolysis in the main body of the cell to generate energy, producing lactate as a byproduct. This metabolic shift, characterized by increased activity of the enzyme lactate dehydrogenase (LDH), mimics the state of highly active, proliferative stem cells. This change in the internal environment acts as an unambiguous signal for the dormant hair follicle stem cell to re-enter the growth (anagen) phase and begin the process of producing a new hair fiber.   

This approach is what defines PP405 as a true “regenerative medicine” therapy. It is not masking a symptom or fighting an external aggressor; it is reactivating the body’s own innate capacity to grow hair.   

The Old Guard vs. The New Paradigm: A Head-to-Head Comparison

To fully appreciate the significance of PP405, it is essential to contrast its mechanism with the two most common FDA-approved treatments: minoxidil and finasteride. For decades, these have been the only scientifically validated options, but they operate on entirely different principles and come with their own sets of limitations.   

Minoxidil (Rogaine) was originally an oral medication for high blood pressure. Its hair-growing properties were an accidental discovery. Its exact mechanism is still not fully understood, but it is known to be a vasodilator, meaning it widens blood vessels, which may improve blood and nutrient flow to the follicle. It is also a potassium channel opener, which is thought to help shorten the resting phase and prolong the growth phase of the hair cycle. However, its effects are often modest, sometimes producing only fine, “peach fuzz” hair, and it does not address the underlying cause of follicular dormancy.   

Finasteride (Propecia) works by tackling the hormonal cause of male pattern baldness. It is a 5-alpha-reductase inhibitor, an enzyme that converts testosterone into the more potent androgen, dihydrotestosterone (DHT). In genetically susceptible individuals, DHT binds to receptors in the hair follicles, causing them to shrink (miniaturize) and eventually stop producing hair. By reducing DHT levels, finasteride can halt this process and, in some cases, reverse it. Its primary limitation is its hormonal mechanism; it is an oral drug with systemic effects and is not suitable for women. Some men also experience sexual side effects.   

PP405 represents a new paradigm. It bypasses the hormonal pathways targeted by finasteride and the poorly understood vascular effects of minoxidil. Because it targets a fundamental metabolic process common to all hair follicle stem cells, it holds the potential to be effective for both men and women, across all hair and skin types, without systemic hormonal disruption.   

Part III: The Gauntlet: From Lab Bench to Human Scalps

Decoding the Data – The Clinical Trial Journey

A promising scientific theory is one thing; proving it works safely and effectively in humans is another. The journey of PP405 from the lab bench to the medicine cabinet is a story told through the rigorous, multi-stage process of clinical trials. The data emerging from these trials has been the driving force behind the growing excitement and investment.

The initial myth of a “one-week cure” stems from a misunderstanding of the trial phases. The first human study, Phase 1, was designed primarily to test for safety, tolerability, and, critically, proof of mechanism. In this trial, participants applied a 0.05% PP405 topical gel for just seven days. The results were pivotal: the treatment was found to be safe and well-tolerated, with no detectable absorption into the bloodstream, confirming its localized action. Most importantly, biopsies of the treated scalp tissue showed a statistically significant increase in   

Ki67, a well-established molecular marker for cell proliferation. This was the smoking gun. In just one week, PP405 had successfully “flipped the switch” and told the dormant stem cells to start dividing. It proved the science worked in humans.   

This successful proof of mechanism was the green light for the Phase 2a trial, which began in mid-2024. This phase is designed to evaluate safety in a larger group and to look for the first real signs of   

efficacy—actual hair growth. The trial enrolled 78 men and women with androgenetic alopecia, including a diverse range of skin and hair types, a conscious effort to ensure broad applicability. In this study, participants applied the gel daily for four weeks and were monitored for up to 12 weeks.   

The early results from this Phase 2a trial, announced in mid-2025, were nothing short of stunning and are what truly propelled PP405 into the spotlight. Among men with a higher degree of hair loss, 31% of those treated with PP405 showed a greater than 20% increase in hair density just eight weeks after starting the trial (four weeks after treatment ended). By contrast, 0% of the placebo group saw such an improvement. This result is remarkable for two reasons. First, the magnitude of the response in a significant portion of the treatment group is highly encouraging. Second, the speed is unprecedented. Visible results from existing treatments like minoxidil or finasteride typically require 6 to 12 months of continuous use. PP405 demonstrated a measurable, significant effect in a fraction of that time, suggesting a powerful and rapid regenerative capability.   

The Pelage Powerhouse and the Google Stamp of Approval

The translation of this groundbreaking UCLA research into a potential commercial product is being managed by Pelage Pharmaceuticals, a startup co-founded by the scientific trio of Lowry, Christofk, and Jung. The company was formed through UCLA’s Technology Development Group, which helps shepherd brilliant academic discoveries into the marketplace, and exclusively licensed the intellectual property for PP405 and related molecules in 2018.   

The trajectory of Pelage demonstrates a powerful, virtuous cycle where strong science attracts significant capital, which in turn accelerates further research. The initial promise of the science was enough to get the company off the ground. However, the real catalyst was the positive data from the clinical trials.

In February 2024, on the back of promising preclinical work and the initiation of the Phase 1 trial, Pelage announced it had closed a $16.75 million Series A financing round led by GV (formerly Google Ventures), with participation from other key investors. This investment from one of Silicon Valley’s most respected venture capital firms was a massive vote of confidence. Cathy Friedman, Executive Venture Partner at GV and a Pelage board member, noted, “GV is excited by the incredible science behind the Pelage technology… moving beyond agents that merely slow the progression of hair loss to a treatment solution that actually helps to regrow hair”.   

The validation loop then spun faster. Following the release of the successful Phase 1 data demonstrating safety and the crucial Ki67 activation, Pelage secured an additional $14 million in a Series A-1 financing round in August 2024, again led by GV. This new infusion of capital was explicitly earmarked to “accelerate its Phase 2 clinical program”. This sequence of events is a clear illustration of how the modern biotech ecosystem functions: robust, data-driven scientific validation unlocks the financial resources necessary to navigate the long and expensive path of clinical development and regulatory approval. The GV stamp of approval is more than just money; it is a powerful endorsement of the quality of the science and the potential of the technology to disrupt a multi-billion dollar market.   

Part IV: The Horizon and Beyond

The Road to the Medicine Cabinet: Timelines, Trials, and Tribulations

While the early data is exceptionally promising, PP405 is not yet ready for public use. The path to the medicine cabinet is a marathon, not a sprint, governed by the rigorous safety and efficacy standards of the U.S. Food and Drug Administration (FDA).

Following the current Phase 2a trial, Pelage Pharmaceuticals will need to conduct a larger, more definitive Phase 3 trial. This phase typically involves hundreds or even thousands of patients and is designed to confirm the efficacy and safety observed in earlier trials on a much larger scale. This is the final and most expensive step before a company can submit a New Drug Application (NDA) to the FDA for approval.

Given the standard timelines for these processes, industry experts and the company project that a PP405-based treatment could potentially reach the market between 2027 and 2030, pending successful outcomes in all remaining trials.   

An interesting note in the public trial registry is the mention of “Expanded Access”. This is a potential pathway through which patients with serious or immediately life-threatening conditions who cannot participate in a clinical trial may gain access to an investigational drug outside of the trial setting. While hair loss is not typically considered life-threatening, this provision indicates a mechanism exists for specific cases, though its application here remains to be seen.   

Crucially, the potential impact of PP405 may extend far beyond common pattern baldness (androgenetic alopecia). Because its mechanism targets the fundamental biology of the hair follicle stem cell—waking it from dormancy—it is agnostic to what caused the dormancy in the first place. This has led researchers and the company to investigate its potential for other types of hair loss. Pelage is actively developing PP405 for chemotherapy-induced alopecia and believes it may also have applications for telogen effluvium, or stress-induced hair loss. This transforms PP405 from a single product into a potential platform technology, capable of addressing a wide spectrum of alopecia conditions and dramatically expanding its medical and commercial significance.   

The Regenerative Revolution: If We Can Awaken Hair, What’s Next?

Zooming out from the immediate goal of curing baldness, the story of PP405 offers a tantalizing glimpse into the future of medicine. The core principle—using a small molecule to reprogram the metabolism of a dormant stem cell to trigger a regenerative process—is a landmark achievement. It serves as a powerful proof-of-concept for a new therapeutic strategy.  

The human body is replete with slumbering or hibernating cells in various tissues—cells that are not dead, but are no longer active. The questions that PP405 raises are profound. If we have found the molecular “alarm clock” for hair follicle stem cells, can we find similar keys for other cell types? Could we, in the future, awaken dormant cardiac cells to repair a damaged heart, or neural stem cells to restore function after a stroke?   

This is the grand promise of regenerative medicine: shifting the focus from treating symptoms or blocking disease pathways to actively restoring the body’s own incredible, innate ability to heal and rebuild itself. The work of Lowry, Christofk, and Jung began as an inquiry into the fundamental rules of life, cancer, and metabolism. It has resulted in a potential solution to one of humanity’s most common afflictions. But its true legacy may be even greater. It may be remembered not just for the hair it regrew, but for the new chapter it opened in our quest to unlock the restorative power hidden within our own cells.

References

1. Bauman Medical. (2025). Pelage PP405 Stimulates Hair Follicle Stem Cells via Mitochondria in Phase 1 Trial. Retrieved from https://www.baumanmedical.com/pelage-pp405-stimulates-hair-follicle-stem-cells-via-mitochondria-in-phase-1-trial/   
2. Buhl, A. E., Waldon, D. J., Baker, C. A., & Johnson, G. A. (1990). Minoxidil sulfate is the active metabolite that stimulates hair follicles. Journal of Investigative Dermatology, 95(5), 553–557. https://doi.org/10.1111/1523-1747.ep12504905   
3. Business Wire. (2025, June 17). Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy. Retrieved from https://www.businesswire.com/news/home/20250617338859/en/Pelage-Pharmaceuticals-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-PP405-in-Regenerative-Hair-Loss-Therapy   
4. ClinicalTrials.gov. (2025). Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (Identifier NCT06393452). U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/study/NCT06393452   
5. DrugTopics. (2025). Hair Loss Therapy Shows Potential for Regeneration in Phase 2 Trial. Retrieved from https://www.drugtopics.com/view/hair-loss-therapy-shows-potential-for-regeneration-in-phase-2-trial   
6. Finsmes. (2024, August). Pelage Pharmaceutical Raises $14M Series A-1 Funding. Retrieved from https://www.finsmes.com/2024/08/pelage-pharmaceutical-raises-14m-series-a-1-funding.html   
7. Gupta, A. K., & Charrette, A. (2023). The role of finasteride in the treatment of androgenetic alopecia. Journal of Dermatological Treatment, 34(1), 2154231.   
8. iHeart. (2025, May 15). New UCLA Discovery Could Help Regrow Real Hair by 2027. Retrieved from https://www.iheart.com/content/2025-05-15-new-ucla-discovery-could-help-regrow-real-hair-by-2027/   
9. Messegué, F., et al. (2022). Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. Dermatologic Therapy, 35(10), e13059. https://doi.org/10.1111/dth.13059   
10. Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186–194. https://doi.org/10.1111/j.1365-2133.2004.05785.x   
11. Pelage Pharmaceuticals. (n.d.). A New Approach to Hair Loss Grounded in Stem Cell Biology. Retrieved from https://pelagepharma.com/   
12. PR Newswire. (2024, February 27). Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss. Retrieved from https://www.prnewswire.com/news-releases/pelage-pharmaceuticals-announces-16-75m-series-a-financing-led-by-gv-to-revolutionize-regenerative-medicine-for-hair-loss-302071733.html   
13. PR Newswire. (2024, March 9). Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study. Retrieved from https://www.prnewswire.com/news-releases/pelage-presents-late-breaking-data-at-aad-2024-meeting-demonstrating-pp405-activates-human-hair-follicle-stem-cells-ex-vivo-and-in-phase-1-clinical-study-302084610.html   
14. StatPearls. (2023). Androgenetic Alopecia. NCBI Bookshelf. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK430924/   
15. Stubbs Alderton & Markiles, LLP. (2024). SA&M Client Pelage Pharmaceuticals Secures $14M Series A-1 Financing. Retrieved from https://stubbsalderton.com/sam-client-pelage-pharmaceuticals-secures-14m/   
16. Synapse. (n.d.). Pelage Pharmaceuticals Reports Positive Phase 2a Trial Results for PP405 in Hair Loss Therapy. PatSnap. Retrieved from https://synapse.patsnap.com/article/pelage-pharmaceuticals-reports-positive-phase-2a-trial-results-for-pp405-in-hair-loss-therapy   
17. Synapse. (n.d.). Pelage secures $14M from GV, starts Phase II for alopecia. PatSnap. Retrieved from https://synapse.patsnap.com/article/pelage-secures-14m-from-gv-starts-phase-ii-for-alopecia   
18. UCLA Broad Stem Cell Research Center. (n.d.). Heather Christofk, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/heather-christofk-phd   
19. UCLA Broad Stem Cell Research Center. (n.d.). Michael E. Jung, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/michael-e-jung-phd   
20. UCLA Broad Stem Cell Research Center. (n.d.). William Lowry, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/william-lowry-phd   
21. UCLA Newsroom. (2019, May 28). UCLA licenses technology to combat hair loss to company founded by faculty members. Retrieved from https://newsroom.ucla.edu/releases/hair-loss-drug-formula-licensed   
22. UCLA Newsroom. (2025, February 4). Did UCLA just cure baldness?. UCLA Magazine. Retrieved from https://newsroom.ucla.edu/magazine/baldness-cure-pp405-molecule-breakthrough-treatment   
23. Various Authors. (n.d.). Mechanism of action of minoxidil for hair loss. PubMed. Retrieved from various sources.   

The post Permanent Cure for Baldness? Inside the Google-Backed Quest to Awaken Sleeping Hair Follicles first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

The Brain’s Private Cinema: What Happens When We Dream

Most of our vivid, story-like dreams occur during a stage of sleep called REM (Rapid Eye Movement). As we enter this stage, our brain undergoes a dramatic transformation. Brain scans show a surge of activity in key areas:

The amygdala and hippocampus, the brain’s deep emotional and memory centers, are fired up, which is why dreams are often emotionally charged and draw on our past experiences.

The visual cortex is highly active, creating the rich imagery of our dream worlds.

Crucially, the prefrontal cortex, the logical, rational “CEO” of the brain located just behind our forehead, is significantly dampened. This lack of executive control is why dreams are so illogical, why we readily accept bizarre plots, and why our critical thinking is offline.

At the same time, the brainstem sends signals that paralyze the body’s voluntary muscles, a state called muscle atonia. This vital safety feature prevents us from physically acting out our dreams, ensuring we don’t leap out of bed while dreaming we can fly.

The Overnight Therapist: Processing Emotions

One of the most important jobs of dreaming appears to be a form of overnight therapy. Neuroscientist Matthew Walker, author of Why We Sleep, champions the “sleep to forget, sleep to remember” hypothesis. The theory proposes that during REM sleep, our brain re-processes emotional memories from the day. However, it does so in a unique neurochemical state where stress-related molecules, like noradrenaline, are completely absent.

This allows the brain to replay the memory and its associated feelings without the accompanying stress. In doing so, it can “strip the painful emotional charge, or the sharp affective edges, from the memory,” as Walker puts it. We retain the memory of the event, but its emotional sting is softened. This is why, after a good night’s sleep, we often wake up feeling better about something that was deeply upsetting the day before. Dreaming helps us heal.

The Ultimate Simulator: Rehearsing for Reality

Another powerful theory suggests that dreaming is our brain’s own private VR simulator. The Threat Simulation Theory (TST), proposed by Finnish philosopher and neuroscientist Antti Revonsuo, argues that dreaming evolved as a survival mechanism. Our ancestors’ world was filled with dangers, and dreams provided a safe, virtual space to rehearse threatening scenarios—being chased by a predator, fighting an enemy, or falling from a height. By practicing these situations repeatedly, our brains could fine-tune our threat-perception and avoidance skills, giving us an edge in the real world. This could explain why anxiety dreams are so common.

This idea can be expanded to Social Simulation. Dreams often feature complex and emotionally charged social interactions. In the same way we practice for physical threats, our brains may use dreams to simulate social scenarios, helping us navigate relationships, understand social cues, and prepare for challenging conversations.

The Memory Consolidator and Creative Engine

Beyond emotions and threats, dreaming plays a vital role in learning and creativity. During the day, our brains take in a huge amount of information. At night, dreaming helps consolidate these memories. The hippocampus replays events from the day, and the brain strengthens important connections while pruning away weaker, less relevant ones. This process is crucial for solidifying new knowledge and mastering new skills, whether learning a language or practicing a tennis serve.

This process can also lead to flashes of insight. In the strange, hyper-associative state of the dreaming brain, where logic is turned down, our minds can connect seemingly unrelated ideas. This can lead to novel solutions to problems we’re stuck on. Famous (though perhaps apocryphal) stories credit dreams with sparking world-changing ideas, from the structure of the benzene ring to the creation of the periodic table.

A surprising fact: People who are blind from birth still experience rich, complex dreams. Their dream worlds are not built from visual imagery but from their other senses: sound, touch, taste, and smell. This demonstrates that dreaming is a fundamental cognitive process, not just a visual replay.

Modern research, some of which is being conducted in Australian institutions like the Florey Institute of Neuroscience and Mental Health, continues to unravel this mystery. Using AI to analyze the brain activity of sleeping subjects, we are getting closer to “reading” the content of dreams, confirming that this nightly job is anything but random.

Dreams are our brain’s multi-purpose tool for healing our emotions, preparing us for challenges, cementing our memories, and sparking our creativity. As we continue to decode the secrets of our sleeping brain, we’re realizing that a third of our life is not spent in stasis, but in a vital state of mental recalibration. What other profound human abilities are being shaped in the secret theater of our dreams?

References

1. Walker, M. (2017). Why We Sleep: Unlocking the Power of Sleep and Dreams. Scribner/Simon & Schuster.
2. Revonsuo, A. (2000). The reinterpretation of dreams: An evolutionary hypothesis of the function of dreaming. Behavioral and Brain Sciences, 23(6), 877-901.
   • Link: https://www.cambridge.org/core/journals/behavioral-and-brain-sciences/article/reinterpretation-of-dreams-an-evolutionary-hypothesis-of-the-function-of-dreaming/4C204B7059EB265147C74567A868B44A
3. Payne, J. D., & Nadel, L. (2004). Sleep, dreams, and memory consolidation: the role of the stress hormone cortisol. Learning & Memory, 11(6), 671-678.
   • Link: https://learnmem.cshlp.org/content/11/6/671.full
4. Horikawa, T., Tamaki, M., Miyawaki, Y., & Kamitani, Y. (2013). Neural Decoding of Visual Imagery During Sleep. Science, 340(6132), 639-642.
   • Link: https://doi.org/10.1126/science.1234330
5. Hobson, J. A. (2009). REM sleep and dreaming: towards a theory of protoconsciousness. Nature Reviews Neuroscience, 10(11), 803-813.
   • Link: https://www.nature.com/articles/nrn2716

The post The Brain’s Secret Overnight Job: New Theories on Why We Dream first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

What is VR Therapy? More Than Just a Distraction

When many people think of VR, they picture immersive video games. But therapeutic VR is far more than a simple distraction. It is the use of carefully designed, interactive virtual environments to achieve specific clinical goals. In a VR therapy session, the patient is not just a passive observer; they are an active participant in a world the therapist can control and customize in real-time.

The therapist can introduce challenging elements gradually, monitor the patient’s biometric data (like heart rate and stress levels), and provide guidance throughout the simulated experience. This creates a powerful feedback loop: the brain perceives the simulation as real enough to engage with, but the patient remains physically safe, allowing them to learn and adapt in a controlled setting. It’s the perfect bridge between imagination and reality.

Re-writing Fear: Exposure Therapy in a Headset

One of the most successful applications of VR therapy is in treating anxiety disorders and phobias through exposure therapy. The goal of this therapy is to gradually expose a person to their feared stimulus in a safe environment until the fear response diminishes. VR makes this process safer, more accessible, and more controllable than ever before.

Treating Phobias: Someone with a fear of flying can put on a headset and find themselves in a virtual airport. They can board the plane, sit through takeoff, and even experience turbulence, all while their therapist guides them through coping techniques. For a fear of heights, they might ride a virtual glass elevator. For arachnophobia, a therapist can introduce a single, small virtual spider and slowly increase its size or number based on the patient’s progress.

Treating PTSD: VR has become a vital tool for helping military veterans and others suffering from Post-Traumatic Stress Disorder. Programs like “Bravemind,” developed at the University of Southern California, allow therapists to create customised virtual environments that resemble the source of a patient’s trauma. In this secure space, the patient can confront and re-process painful memories, gradually reducing their emotional hold. This process, known as Prolonged Exposure, helps the brain learn that the memory is no longer a present threat.

The Brain’s Perception of Pain: A New Frontier

Perhaps the most surprising benefit of VR is its remarkable ability to manage pain. Pain is not just a physical signal; it is an experience constructed by the brain. VR can powerfully influence this construction.

Acute Pain Relief: Numerous studies, including those at hospitals here in Australia, have shown that immersing a patient in an engaging virtual world can dramatically reduce acute pain during procedures like changing burn dressings or dental work. The immersive sensory input of the virtual world is so demanding that it diverts the brain’s attentional resources, essentially crowding out the pain signals. Some studies have found it can be more effective than morphine.

Chronic Pain and Rehabilitation: For those with chronic pain or recovering from an injury, VR offers new hope. Gamified physical therapy programs can make monotonous rehabilitation exercises more engaging, leading to better patient adherence and faster recovery. For stroke patients, seeing a virtual limb move correctly in response to their efforts can help remap neural pathways in the brain—a process called neuroplasticity—and restore function to a paralyzed limb.

A surprising fact: The effects of successful VR therapy are not just psychological; they are physical. Brain scans taken before and after VR exposure therapy for phobias have shown tangible changes. The connections in the prefrontal cortex (the part of the brain responsible for logic and reasoning) become stronger, while the fear response generated by the amygdala becomes weaker.

As this technology becomes more affordable and accessible, institutions across Australia, from the University of South Australia’s’s Innovation & Collaboration Centre to major hospitals, are increasingly researching and adopting VR for everything from mental health support to stroke recovery, placing us at the forefront of this medical revolution.

VR is maturing from a novelty into a legitimate medical device. It provides a unique and powerful way to treat the human mind by creating worlds specifically designed to help it heal. As these virtual realities become ever more realistic, what other aspects of human health will be transformed by our ability to recover within a simulated world?

References

1. Rizzo, A. “Skip”, & Shilling, R. (2017). Clinical Virtual Reality: A New Tool for Health and Wellness. Annual Review of CyberTherapy and Telemedicine, 15.
   • Link:https://www.researchgate.net/publication/323381014_Clinical_Virtual_Reality_A_New_Tool_for_Health_and_Wellness
2. Hoffman, H. G., Chambers, G. T., Meyer, W. J., et al. (2011). Virtual reality as an adjunctive non-pharmacologic analgesic for pain control during burn wound care. Pain, 152(5), 1089-1095.
   • Note: A key study on VR for pain management.
   • Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782803/
3. Parsons, T. D., & Riva, G. (2016). Virtual Reality in Clinical Assessment and Neuropsychology. Studies in health technology and informatics, 220, 277-283.
   • Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414474/
4. University of South Australia. (2025). VR technology to help people with brain injuries.
   • Link: https://www.unisa.edu.au/media-centre/Releases/2025/vr-technology-to-help-people-with-brain-injuries/
5. Freeman, D., Reeve, S., Robinson, A., et al. (2017). Virtual reality in the assessment, understanding, and treatment of mental health disorders. Psychological medicine, 47(14), 2393-2400.
   • Link: https://www.cambridge.org/core/journals/psychological-medicine/article/virtual-reality-in-the-assessment-understanding-and-treatment-of-mental-health-disorders/2A5557F1388A41A1B45A4543F01C313C

The post Healing in a Virtual World: The Surprising Power of VR Therapy first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

What Exactly Is a Nanobot? From Sci-Fi to Reality

When we hear “nanobot,” we might picture a tiny, metallic robot with gears and propellers, shrunken down to an impossible size. The reality is both more subtle and more elegant. A nanobot is any robotic device operating at the nanoscale (a nanometer is one-billionth of a meter). At this scale, scientists aren’t building with metal and wires; they’re building with the molecules of life itself.

The leading “real-world” nanobots are built from DNA. Through a technique called DNA origami, scientists can fold long strands of DNA into specific, three-dimensional shapes. They can create a hollow box with a lid, a cage, or a barrel. This DNA structure acts as the nanobot’s body, capable of carrying a payload—like a potent dose of a chemotherapy drug.

The “brain” of this nanobot is a set of molecular triggers. The DNA box can be designed with “locks” made of special DNA sequences called aptamers. These locks are programmed to open only when they encounter a specific target protein found exclusively on the surface of a cancer cell. This means the nanobot can circulate harmlessly through the entire body, ignoring healthy tissue. But upon finding its target, it unlocks, opens up, and delivers its deadly cargo directly to the cancer cell, leaving everything else untouched.

The Missions: What Could Nanobots Do Inside Us?

The potential applications of these nanoscopic machines are poised to transform every aspect of healthcare, moving us from an era of treatment to one of pre-emption and precision.

Targeted Drug Delivery: This is the most developed application. By loading nanobots with powerful drugs, we can attack diseases at their source without collateral damage. This would mean drastically reducing the debilitating side effects of treatments like chemotherapy and using drugs that were previously considered too toxic for systemic use.

Early Disease Detection: Imagine nanobots acting as tiny patrol guards in your bloodstream. These “nanosensors” could be designed to search for the faintest chemical traces of disease—the specific proteins shed by a tiny, nascent tumor or the early signs of plaque forming in an artery. Upon detecting these signals, they could send a report to an external device like a smartwatch, alerting you to a disease years before any symptoms appear.

Precision “Nanosurgery”: This is the more futuristic, but awe-inspiring, vision. Researchers are designing nanobots that can perform physical tasks. For example, tiny, propeller-driven bots guided by external magnetic fields could travel upstream through arteries to break up blood clots that cause strokes. Others could identify and destroy individual bacteria or viruses, offering a solution to antibiotic-resistant superbugs.

A surprising fact: The vision of nanomedicine was first proposed by Nobel Prize-winning physicist Richard Feynmanin his legendary 1959 lecture, “There’s Plenty of Room at the Bottom.” He theorized about the possibility of creating nanoscale machines and famously imagined a future where you could “swallow the doctor.”

The Hurdles on the Nanoscale

While the promise is immense, sending a trillion robots into the human body comes with incredible challenges.

• Power and Propulsion: How do you power a machine smaller than a cell? Some nanobots are designed to be passive, simply flowing with the blood. Others are propelled by external forces like magnetic fields or ultrasound. Ingeniously, some are powered by chemistry—tiny rockets coated in zinc that react with stomach acid to produce hydrogen gas bubbles, pushing them forward.
• Biocompatibility: The human immune system is designed to attack any foreign invader. Nanobots must be built from materials that are either ignored by the immune system (like DNA) or are coated in a biological “stealth cloak.”
• Control and Removal: Once their mission is complete, what happens to them? The most elegant solution is to build them from biodegradable materials. DNA nanobots, for instance, simply break down and are recycled by the body’s natural processes within a few days.

Another little-known fact: The first majorly successful trial of nanobots in a living mammal has already happened. In a 2018 study published in Nature Biotechnology, researchers from Arizona State University injected DNA nanobots into mice with cancerous tumors. The nanobots successfully sought out the tumors and delivered a drug that triggered blood clotting, cutting off the tumor’s blood supply and causing it to shrink and decay without harming the host mouse.

The era of nanoscale medicine is no longer a distant dream. While the autonomous nanosurgeon from science fiction is still decades away, the first generation of microscopic medics is already here, promising to make medicine smarter, safer, and more precise than ever before.

As we prepare to unleash these tiny doctors into our bodies, we are creating a new paradigm of healthcare from the inside out. What will medicine look like when our treatments are smaller than our cells, and what does it mean to be “healthy” in a world where disease can be stopped before it even begins?

References

1. Feynman, R. P. (1960). There’s Plenty of Room at the Bottom. Engineering and Science, 23(5), 22-36.
   • Link: https://calteches.library.caltech.edu/1976/1/1960_02_Feynman.pdf
2. Li, S., Jiang, Q., Liu, S., et al. (2018). A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology, 36, 258–264.
   • Link: https://doi.org/10.1038/nbt.4071
3. Douglas, S. M., Bachelet, I., & Church, G. M. (2012). A logic-gated nanorobot for targeted transport of molecular payloads. Science, 335(6070), 831-834.
   • Link: https://doi.org/10.1126/science.1214081
4. Wang, J. (2009). Can Man-Made Nanomachines Compete with Nature Biomotors? ACS Nano, 3(1), 4-9.
   • Link: https://doi.org/10.1021/nn800841p
5. Service, R. F. (2018, February 12). DNA ‘robots’ successfully treat cancer in mice. Science.
   • Link: https://www.science.org/content/article/dna-robots-successfully-treat-cancer-mice

The post Microscopic Medics: How Nanobots Will Revolutionize Healthcare first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

The Discovery in the Dumpster: Meet Ideonella sakaiensis

The story begins in 2016, not in a pristine laboratory, but in the grime outside a plastic bottle recycling plant in Sakai, Japan. A team of scientists was sifting through sediment, hunting for microbes that might be interacting with the plastic waste. There, they isolated a new species of bacterium, which they named Ideonella sakaiensis. Under the microscope, they witnessed something extraordinary. This tiny organism was using plastic as its primary food source.

Specifically, it was consuming Polyethylene terephthalate (PET), the ubiquitous plastic used to make single-use drink bottles. The bacterium had evolved a unique two-step process to do this. It secretes a special enzyme, now called PETase, which acts like a first-stage chemical scissors, breaking down the tough polymer surface of the plastic into smaller, manageable molecules (a monomer called MHET). Then, a second enzyme, MHETase, pulls these molecules inside the cell and breaks them down further into their basic chemical building blocks. The bacterium could then use these building blocks for energy and growth.

This was a landmark discovery. It was the first time an organism had been found that could completely break down and metabolize PET plastic. It was as if, in the 70-odd years since plastic became common, nature had already evolved a specific “knife and fork” to consume it.

A Global Army of Microbes is Evolving

For a time, Ideonella sakaiensis seemed like a fascinating fluke. But scientists soon realized it was just the first sign of a global evolutionary event. By searching through huge genetic databases from environmental samples, researchers have now identified hundreds of other potential plastic-degrading enzymes in microbes from all over the world, from the deepest oceans to the highest mountains.

This isn’t limited to just bacteria or just PET plastic. Researchers have found:

• A soil fungus, Aspergillus tubingensis, which can break down polyurethane (PU), a plastic commonly used in adhesives, foam, and insulation.
• The gut bacteria inside mealworms and wax worms have been shown to degrade polystyrene (Styrofoam), one of the most notoriously difficult plastics to recycle.
• Other microbes that show potential for breaking down different types of polymers, suggesting nature is mounting a multi-pronged attack on our waste.

A surprising fact: This evolution is happening at astonishing speed. Life has been dealing with materials like wood and cellulose for billions of years. Plastic has only been mass-produced for about 70 years. For microbes to have developed entirely new enzymatic pathways to digest this synthetic material in such a tiny evolutionary window is a stunning testament to the adaptability of life. Scientists now refer to the ecosystem of microbes living on floating plastic debris as the “Plastisphere,” a new man-made habitat that is serving as a hotbed for this rapid evolution.

From Lab Bench to Landfill: Can We Supercharge These Microbes?

While this is incredibly exciting, we can’t simply release these bacteria into our oceans and landfills and expect them to clean up our mess. The natural process is extremely slow, and the environmental conditions are far from optimal. The real solution lies in harnessing their power and putting it on steroids.

This is where biotechnology comes in. Scientists are now using protein engineering to create “super-enzymes.” They take the naturally occurring PETase enzyme and use AI and lab techniques to introduce mutations that make it far more effective. In 2020, a team created an enzyme that could break down plastic six times faster than the 2016 version.

The French company Carbios is already commercializing this. They have developed an engineered enzyme that can operate at high temperatures, allowing it to break down 90% of a PET bottle into its constituent parts in just 10 hours. This is the ultimate goal: biological recycling. Instead of melting plastic down (which degrades its quality), we can use these enzymes in large bioreactors to chemically de-polymerize our waste. This process breaks plastic down to its pure, original chemical building blocks, which can then be used to create new, virgin-quality plastic over and over again, creating a truly circular economy.

Another little-known fact: One of the first “super-enzyme” breakthroughs was a partial accident. In 2018, scientists were studying the original PETase enzyme and made a mutation to better understand its structure. They inadvertently created a version that was 20% more efficient at degrading plastic, kicking off the global race to intentionally engineer even faster and more robust enzymes.

Nature is showing us a way out of the plastic crisis by evolving a solution in real-time. While these microbes are not a license to continue polluting, they represent a powerful new tool in our arsenal. As we learn to harness and accelerate this natural process, are we witnessing the dawn of biological recycling, and can we deploy it fast enough to clean up the mess we’ve made?

References

1. Yoshida, S., Hiraga, K., Takehana, T., et al. (2016). A bacterium that degrades and assimilates poly(ethylene terephthalate). Science, 351(6278), 1196-1199.
   • Link: https://doi.org/10.1126/science.aad6359
2. Austin, H. P., Allen, M. D., Donohoe, B. S., et al. (2018). Characterization and engineering of a plastic-degrading aromatic polyesterase. Proceedings of the National Academy of Sciences, 115(19), E4350-E4357.
   • Link: https://doi.org/10.1073/pnas.1718804115
3. Carbios. (n.d.). A REVOLUTIONARY ENZYME AT THE HEART OF OUR PROCESSES. Company Website.
   • Link: https://www.carbios.com/en/our-technology/an-enzyme-at-the-heart-of-our-processes/
4. Greshko, M. (2020, October 13). ‘Super-enzyme’ discovery is another leap forward for recycling plastic. National Geographic.
   • Link: https://www.nationalgeographic.com/science/article/super-enzyme-eats-plastic-bottles-recycling
5. Gewert, B., Plassmann, M. M., & MacLeod, M. (2015). The “Plastisphere” – A new marine ecological niche. Environmental Science & Technology Letters, 2(12), 317.
   • Link: https://pubs.acs.org/doi/10.1021/acs.estlett.5b00298

The post Nature’s Cleanup Crew: The Strange Science of Plastic-Eating Bacteria first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

What is CRISPR? The Genetic Scissors We Found in Bacteria

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a name that has dominated headlines, but its origins are surprisingly humble. It was discovered as a natural defense system in bacteria. When a virus attacks a bacterium, the bacterium captures a snippet of the virus’s DNA and stores it in its own genetic code within the CRISPR sequences. It acts as a “most wanted” gallery of past invaders.

If the same virus attacks again, the bacterium produces a guide molecule (guide RNA) from the stored snippet. This guide RNA is like a genetic search engine. It pairs with an enzyme, typically Cas9, which acts as a pair of “molecular scissors.” The guide RNA leads the Cas9 enzyme to the matching viral DNA and snips it, neutralizing the threat.

In the 2010s, scientists, including Nobel laureates Emmanuelle Charpentier and Jennifer Doudna, realized they could hijack this system. By creating their own custom guide RNA, they could direct the Cas9 scissors to cut any DNA sequence in any organism. This allows them to delete faulty genes, insert new ones, and rewrite the code of life with unprecedented precision and ease.

De-Extinction: Resurrecting Giants of the Past

The most audacious goal for CRISPR in conservation is “de-extinction.” Leading this charge is the bioscience company Colossal Biosciences, which has famously announced its intention to bring back the woolly mammoth.

Their method is not true cloning, as intact mammoth cells don’t exist. Instead, they are pursuing a form of genetic engineering. The process involves:

Sequencing the complete woolly mammoth genome from DNA recovered from frozen remains.

Comparing this genome to that of the mammoth’s closest living relative, the Asian elephant.

Using CRISPR to edit the DNA of an Asian elephant cell, changing its genes to match the mammoth’s for key traits like a dense, shaggy coat, a thick layer of subcutaneous fat, smaller ears, and cold-adapted blood.

The goal is to create a “functional mammoth”—a cold-resistant elephant that is genetically a mammoth-elephant hybrid but looks and acts like its extinct cousin. The ultimate vision is to release herds of these animals into the Arctic tundra, where their grazing patterns could help restore the ancient grasslands and combat climate change by preventing permafrost from thawing. Similar projects are underway for the passenger pigeon and the thylacine (Tasmanian tiger).

A surprising fact: The foundation of this futuristic genetic tool was discovered in something quite ordinary: yogurt. Researchers studying the immune systems of Streptococcus thermophilus, a bacterium used in dairy production, were among the first to detail how the CRISPR-Cas9 system targets and destroys viruses, paving the way for its use in gene editing.

Genetic Rescue: Saving the Species We Have Left

While de-extinction grabs headlines, a more immediate and arguably more critical use of CRISPR is “genetic rescue.” Many endangered species suffer from a lack of genetic diversity due to small, isolated populations, making them vulnerable to disease and inbreeding.

CRISPR offers a solution. Scientists can edit the genomes of these animals to boost their resilience. A landmark example is the black-footed ferret. The entire current population is descended from just seven individuals, creating a severe genetic bottleneck. In 2021, scientists successfully cloned a ferret named “Willa” who died over 30 years ago and whose genes were not in the current population. This clone, named “Elizabeth Ann,” represents a vital infusion of lost genetic diversity. CRISPR is being used in this program to potentially edit out inherited disease vulnerabilities.

Beyond animals, CRISPR is being used to save entire ecosystems. The majestic American chestnut tree, once dominant in North American forests, was wiped out by a fungal blight. Using CRISPR, researchers are creating a blight-resistant version of the tree that could one day be restored to its native habitat. Similarly, scientists are exploring how to use CRISPR to make corals more resistant to the thermal stress that causes bleaching, potentially saving our planet’s reefs.

Another little-known fact: CRISPR can create a “gene drive,” a powerful and controversial modification that ensures a specific gene is passed down to almost all offspring, allowing it to spread rapidly through a population. In theory, this could be used to wipe out invasive species or make mosquitoes incapable of carrying malaria. However, the risk of unleashing unintended and irreversible ecological consequences makes it a technology of immense debate.

With the power to rewrite the code of life, we are no longer just stewards of nature; we are becoming its editors. The question is no longer can we, but should we? And as we stand before this new chapter in the history of life, where do we draw the line?

References

1. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
   • Link: https://doi.org/10.1126/science.1258096
2. Colossal Biosciences. (n.d.). The Woolly Mammoth. Company Website.
   • Link: https://colossal.com/mammoth/
3. U.S. Fish & Wildlife Service. (2021, February 18). Black-footed Ferret Conservation Center Welcomes First-Ever Cloned Black-footed Ferret.
   • Link: https://www.fws.gov/story/2021-02/black-footed-ferret-conservation-center-welcomes-first-ever-cloned-black-footed
4. Revive & Restore. (n.d.). The Great Passenger Pigeon Comeback.
   • Link: https://reviverestore.org/projects/passenger-pigeon/
5. Nemet, D. (2021, October 22). CRISPR and the Future of Conservation. Harvard University Graduate School of Arts and Sciences.
   • Link: https://sitn.hms.harvard.edu/flash/2021/crispr-and-the-future-of-conservation/

The post The Power of CRISPR: Editing Genes to Save Species first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

The Plasticity Revolution: A Self-Rewiring Machine

The old belief was that the adult brain was immutable. After a critical period in childhood, its structure was set in stone. Any damage from injury or stroke was permanent. But we now know this is profoundly wrong. The brain is “plastic,” meaning it is malleable and can change its own structure and function in response to experience, or in this case, injury. This self-repair happens through several incredible mechanisms.

One of the primary methods is functional reorganization, or cortical re-mapping. Think of the brain’s cortex as a map, with specific territories dedicated to controlling different parts of your body—a hand area, a face area, an arm area, and so on. When the “hand area” is damaged by a stroke, its neurons die. At first, the connection is lost. But the brain abhors a vacuum. The neighboring, healthy territories—like the arm and face areas—can invade the now-silent hand territory. Through intensive training, these neurons can learn a new job. The area that once controlled the arm can learn to take over the function of the hand, forging new pathways to restore movement. It’s like a company re-assigning employees from a closed department to a new one and retraining them for a different role.

Another mechanism is axonal sprouting. Neurons communicate via long, wire-like appendages called axons. When an injury severs these connections, healthy neurons nearby can sprout new axons, like a plant growing new branches, to connect with the neurons that were cut off from their original partners. They create biological detours, building new communication lines around the damaged zone to restore the flow of information.

Hacking the Reboot: Therapies That Supercharge Plasticity

Understanding that the brain can rewire itself is one thing; making it happen is another. The most exciting frontier in rehabilitation medicine is developing therapies that actively encourage and guide this process.

• Constraint-Induced Movement Therapy (CIMT): This brilliantly simple therapy involves restraining the patient’s “good” or unaffected limb, forcing them to use the stroke-affected limb for hours a day. This massive increase in use bombards the brain with sensory input and motor commands related to the weak limb. It’s an aggressive form of physical therapy that essentially forces the brain to pay attention to the damaged area and accelerates the cortical re-mapping process.

• Brain-Computer Interfaces (BCIs) and Virtual Reality (VR): This is where healing gets futuristic. For a patient with severe paralysis, a BCI can read their brain signals—their intention to move. That signal is then used to control a virtual arm on a screen or a robotic exoskeleton. The patient sees “their” arm moving in response to their thoughts. This creates a powerful visual feedback loop that tricks the brain. Even though the real limb isn’t moving, the brain’s motor circuits are being activated and strengthened, which can rebuild the neural pathways needed to eventually control the real limb again.

A surprising fact: The bizarre phenomenon of phantom limb pain is a direct, albeit negative, result of neuroplasticity. After a hand is amputated, its corresponding brain area is left silent. As the neighboring “face area” invades this territory, a touch on the patient’s cheek can be misinterpreted by the brain as a sensation in the missing hand—often a painful one. Pioneering neuroscientist V.S. Ramachandran famously treated this by using a “mirror box” to trick the brain into “seeing” the phantom limb move, thereby relieving the pain.

The Brain’s Ongoing Update

Neuroplasticity isn’t just for injury recovery; it’s happening in your brain right now. Every new skill you learn, every memory you form, involves physically changing the connections between your neurons.

Here’s another little-known fact: This process can physically change the size of brain regions. A landmark study of London taxi drivers, who must memorize the city’s labyrinthine 25,000 streets, found that they had a significantly larger hippocampus—the brain region associated with spatial memory—than the general population. Their brains had physically grown to accommodate the immense navigational demands of their job.

In some stroke patients who lose their ability to speak due to damage in the brain’s left hemisphere (the typical language center), intensive therapy can encourage the corresponding area in the right hemisphere to take over some language functions. The brain adapts by calling on a region that normally doesn’t handle speech, a testament to its incredible flexibility.

Neuroplasticity has completely upended our view of the brain. It is not a fragile, static machine but a dynamic, resilient, and constantly adapting universe of connections, with a profound capacity for healing.

If we can learn to guide the brain’s rewiring process to recover from catastrophic injury, what other dormant potentials could we one day learn to unlock within the human mind?

References

1. Ramachandran, V.S., & Rogers-Ramachandran, D. (1996). Synaesthesia in phantom limbs induced with mirrors. Proceedings of the Royal Society B: Biological Sciences, 263(1369), 377-386.
   • Link: https://doi.org/10.1098/rspb.1996.0058
2. Taub, E., Uswatte, G., & Pidikiti, R. (1999). Constraint-Induced Movement Therapy: a new family of techniques with broad application to physical rehabilitation–a clinical review. Journal of Rehabilitation Research and Development, 36(3), 237-251.
   • Link: https://www.rehab.research.va.gov/jour/99/36/3/taub.pdf
3. Maguire, E. A., Gadian, D. G., Johnsrude, I. S., et al. (2000). Navigation-related structural change in the hippocampi of taxi drivers. Proceedings of the National Academy of Sciences, 97(8), 4398-4403.
   • Link: https://doi.org/10.1073/pnas.070039597
4. Nudo, R. J. (2006). Plasticity. NeuroRx, 3(4), 420-427.
   • Link: https://doi.org/10.1016/j.nurx.2006.07.006
5. Bach-y-Rita, P. (2004). Brain plasticity. JAMA, 292(16), 1953.
   • Note: A letter to the editor from one of the founding fathers of modern neuroplasticity research, summarizing its importance.
   • Link: https://doi.org/10.1001/jama.292.16.1953-c

The post Rebooting the Brain: The Surprising Science of How It Heals Itself first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..

The Chemistry of Cold Light: How Bioluminescence Works

At its heart, bioluminescence is a simple, elegant chemical reaction. It typically involves two key ingredients: a light-producing molecule called luciferin (from the Latin lucifer, “light-bringer”) and an enzyme called luciferase. When luciferase acts on luciferin in the presence of oxygen, it triggers a reaction that releases energy in the form of a photon—a particle of light.

What makes this process so remarkable is its incredible efficiency. Unlike a light bulb, which wastes most of its energy as heat, bioluminescence is a “cold light.” Some reactions can convert up to 98% of their energy directly into light, making it one of the most efficient light sources on the planet.

Even more fascinating is that life didn’t just invent this trick once. Scientists have found that bioluminescence has evolved independently at least 40 to 50 different times across the tree of life. While the principle is the same, the specific type of luciferin can be completely different between a firefly, a fungus, and a deep-sea fish. It’s a stunning example of convergent evolution, where nature has repeatedly arrived at the same brilliant solution to surviving in the dark.

A Symphony of Signals: The Many Languages of Light

Living light is a language, used for every aspect of survival in the wild. Creatures have evolved to use it for a dazzling array of purposes.

• To Attract: The most famous examples are for mating and luring prey. Male fireflies produce specific flashing patterns to signal their species and fitness to females. In the crushing dark of the bathyal zone, the deep-sea anglerfish uses a fleshy, glowing lure dangling from its head to entice smaller fish directly into its waiting jaws.

• To Defend: Light can be a powerful defensive weapon. When threatened, the vampire squid ejects a sticky cloud of glowing mucus instead of ink. This luminous smokescreen blinds and confuses predators, allowing the squid to escape into the darkness. Many species of shrimp and krill use a “burglar alarm” tactic—flashing brightly to attract a bigger predator that will go after their attacker.

• To Camouflage: Perhaps the most ingenious use of light is for camouflage. The hatchetfish, which lives in the ocean’s twilight zone, has rows of light-producing organs called photophores on its belly. It uses these to perfectly match the faint sunlight filtering down from above, a technique called counter-illumination. This erases its silhouette, making it effectively invisible to any predators lurking below.

A surprising fact: Some creatures don’t even make their own light; they “steal” it through symbiosis. The small Hawaiian bobtail squid cultivates a specific species of glowing bacteria, Vibrio fischeri, in a special light organ. The squid houses and feeds the bacteria, and in return, the bacteria provide the perfect light source for the squid’s counter-illumination camouflage, which it can turn on and off by controlling the oxygen supply to the bacteria.

Beyond the Deep: Unexpected Glows on Land and Sea

While the deep ocean is home to the most bioluminescent species, this phenomenon can be found in many other environments.

• Foxfire: In damp, decaying forests around the world, certain species of fungi, like the Honey Mushroom, create an eerie, sustained glow known as “foxfire.” Scientists believe this glow may attract nocturnal insects that then help to spread the fungus’s spores.

• Milky Seas: Sailors have long told tales of sailing through vast, eerie stretches of ocean that glow with a uniform, milky white light. This spectacular phenomenon, visible from space, is caused by trillions of bioluminescent bacteria communicating and glowing in unison. On a smaller scale, anyone who has seen waves crash with a blue sparkle has witnessed the protest flashes of billions of dinoflagellates (plankton) being disturbed.

• Glowworm Caves: In the famous caves of Waitomo, New Zealand, the ceilings are adorned with what looks like a starry night sky. These “stars” are actually the larvae of a fungus gnat, Arachnocampa luminosa. They produce a soft blue-green light to lure prey into their dangling, sticky fishing lines of silk.

Another little-known fact: The most common color for bioluminescence is blue-green. This is no accident. Blue light travels the farthest through water, making it the most effective wavelength for long-distance communication and vision in the marine environment, where the vast majority of glowing creatures reside.

As marine biologist and deep-sea explorer Dr. Edith Widder puts it, “Bioluminescence is the language of light in the deep ocean.” It’s a language we are only just beginning to understand.

Bioluminescence gives us a tantalizing glimpse into a world that communicates in a vocabulary of light. With over 80% of our oceans still unexplored, what other luminous creatures and secret signals are waiting to be discovered in the darkness below, and what can they teach us about the boundless creativity of life?

References

1. Widder, E. A. (2010). Bioluminescence in the Ocean: Origins of Biological, Chemical, and Ecological Diversity. Science, 328(5979), 704-708.
   • Link: https://doi.org/10.1126/science.1174269
2. National Oceanic and Atmospheric Administration (NOAA). (n.d.). What is bioluminescence?
   • Link: https://oceanexplorer.noaa.gov/facts/bioluminescence.html
3. Ocean Research & Conservation Association (ORCA). (n.d.). Bioluminescence.
   • Note: Founded by Dr. Edith Widder, ORCA is a key resource for bioluminescence research.
   • Link: https://www.teamorca.org/cfiles/bioluminescence.cfm
4. National Geographic. (n.d.). Bioluminescence. Resource Library.
   • Link: https://education.nationalgeographic.org/resource/bioluminescence/
5. Haddock, S. H. D., Moline, M. A., & Case, J. F. (2010). Bioluminescence in the Sea. Annual Review of Marine Science, 2, 443-493.
   • Link: https://doi.org/10.1146/annurev-marine-120308-081028

The post The Secret World of Bioluminescent Creatures first appeared on Science N Tech | Spark Curiosity. Ignite Innovation..